Actinium Pharmaceuticals (ATNM) Retained Earnings (2010 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Retained Earnings of $417.5 million for Q1 2026, up 206.58% year-over-year from $136.2 million in Q1 2025, and up 2087835.0% quarter-over-quarter from -$20000.0 in Q4 2025.
Actinium Pharmaceuticals (ATNM) Retained Earnings (2010 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Retained Earnings for 17 consecutive years, with $417.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 206.58% year-over-year to $417.5 million; the TTM figure through Mar 2026 stood at $417.5 million (up 206.58% YoY), while the FY2025 annual figure was -$20000.0, down 100.0% from the prior year.
- Retained Earnings grew to $417.5 million in Q1 2026 per ATNM's latest filing, from -$20000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $417.5 million in Q1 2026 and bottomed at -$398.6 million in Q2 2025.
- Historically, Retained Earnings has averaged -$57.2 million across 5 years, with a median of -$278.1 million in 2022.
- Annual changes were most pronounced in 2022 — Retained Earnings surged 239.53% — and 2024, when it sank 196.99%.
- Actinium Pharmaceuticals' Retained Earnings stood at -$288.8 million in 2022, then dropped by 16.91% to -$337.6 million in 2023, then soared by 221.02% to $408.6 million in 2024, then tumbled by 100.0% to -$20000.0 in 2025, then soared by 2087835.0% to $417.5 million in 2026.
- Business Quant data shows ATNM's Retained Earnings at $417.5 million in Q1 2026, -$20000.0 in Q4 2025, and $417.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 4.38 Bn |
| 10 | Actinium Pharmaceuticals | 35.17 Mn | 35.17 Mn | - | 417.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 417.67 Mn |
| Mar 31, 2026 | 417.55 Mn |
| Dec 31, 2025 | -20,000.00 |
| Sep 30, 2025 | 417.53 Mn |
| Jun 30, 2025 | -398.64 Mn |
| Mar 31, 2025 | -391.76 Mn |
| Dec 31, 2024 | 408.55 Mn |
| Sep 30, 2024 | 407.35 Mn |
| Jun 30, 2024 | -357.61 Mn |
| Mar 31, 2024 | -346.25 Mn |
| Dec 31, 2023 | -337.58 Mn |
| Sep 30, 2023 | -328.26 Mn |
| Jun 30, 2023 | -314.98 Mn |
| Mar 31, 2023 | 356.98 Mn |
| Dec 31, 2022 | -288.77 Mn |
| Sep 30, 2022 | -278.12 Mn |
| Jun 30, 2022 | -268.64 Mn |
| Mar 31, 2022 | 329.69 Mn |
| Dec 31, 2021 | -255.75 Mn |
| Sep 30, 2021 | -247.74 Mn |